GlassScriptPhysician profile
Trung D Tran
NPI 1932202983
$800.62
in general payments reported to CMS, 2019-2025
10 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2022: $37.06 · 2023: $162 · 2024: $190 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.07 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $115.59 | 2019-2025 | Repatha, Otezla, Prolia |
| Gilead Sciences, INC. | $95.84 | 2019 | |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $93.89 | 2019 | |
| Glaxosmithkline, LLC. | $84.80 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $79.66 | 2023-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.35 | 2023-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $30.57 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $28.23 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $22.62 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.